poisar

Stocks · News reference

HSBC Maintains Buy on AbbVie, Raises Price Target to $315

Benzinga Newsdesk

HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Sns Insider

    Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

    The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

    BMRNPFEABBVSNYTAK
  2. Reuters Events

    Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off

    Enterprise AI is shifting from experimentation to demonstrating measurable ROI. Companies like FedEx ($3B in cost reductions), Mars (20% top-line growth), and Indeed (70% of matches from AI) are scaling AI beyond pilots, but success requires organizational redesign, clear ownership, and human oversight. Leaders warn that AI can amplify existing organizational weaknesses and autonomous agents need defined spending limits and accountability measures.

    FDXABBVWBDUNHSCHW
  3. Na

    ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

    ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA therapeutics, priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026. AbbVie has agreed to purchase shares in a concurrent private placement for approximately $100 million, resulting in a 4.9% stake in ADARx.

    ABBV
  4. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY